Albany, NY -- (SBWire) -- 05/04/2018 --Dyslexia Drugs Market:Overview
According to the National Health Service in the U.K., dyslexia is a common learning disorder that could create problems in spelling, reading, and writing. Despite normal intelligence, dyslexic patients show several symptoms such as poor understanding of letters and words, confusion with reading, and slow reading and writing. The exact cause of dyslexia is unknown. However, genetic abnormalities in families could play a pivotal role in this disorder. Mostly, pre-school children, school children, and adolescents suffer from dyslexia. There is no single test which can diagnose dyslexia in children.
Increase in population with dyslexia drives demand for dyslexia drugs across the world. Enhanced efficiency of these drugs is also fueling demand. However, low awareness and diagnosis of dyslexia, and stringent regulatory policies are anticipated to hamper the growth of the global dyslexia drugs market. Increase in public health care expenditure on mental health is likely to present significant opportunities in the global dyslexia drugs market during the forecast period.
Download PDF Brochure of Report:
https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=41975
In terms of drug class, the global dyslexia drugs market can be segmented into antihistamine, central nervous stimulant, anti-myoclonic, and others. Based on route of administration, the global market can be categorized into oral, parenteral, and others. In terms of end-user, the global dyslexia drugs market can be classified into psychiatric institutions, rehabilitation centers, home care, and others.
Request to View TOC of Report –
https://www.transparencymarketresearch.com/sample/sample.php?flag=T&rep_id=41975
Geographically, the global dyslexia drugs market can be segmented into five major regions: North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. According to a dyslexia center based in the U.S., one in five students or 15% to 20% of the student population suffered from dyslexia in the country, whereas over 15% of the students suffered from dyslexia in Canada in 2016. The National Health Service in the U.K. estimated that around 20% of the children suffered from dyslexia in the U.K. in 2016. A Europe-based survey found that over 20% in France and 15% in Germany were affected with dyslexia in the same year. North America and Europe are anticipated to account for significant shares of the global dyslexia drugs market in 2016 due to high prevalence of dyslexia, high diagnosis and treatment rate, robust psychiatric health care facilities, and presence of key players. Around 15 in 100 students per year are found to be dyslexic in India and 35 million to 40 million children suffered from dyslexia in India in 2016. A study published in the Asian Journal of Psychiatry in 2017 revealed that the number of students with dyslexia increased by nearly 2% in the past five years. Asia Pacific held the third-largest share of the global dyslexia drugs market in 2016. The market in the region is projected to grow at a rapid pace during the forecast period, due to increase in number of students with dyslexia, rise in awareness about dyslexia, availability of generic drugs, and participation of domestic players. Latin America and Middle East & Africa are smaller markets, owing to low awareness, diagnosis and treatment rate of dyslexia, and feeble mental health infrastructure.
Key players in the global dyslexia drugs market include GlaxoSmithKline, Pfizer, Sandoz International GmbH (a Novartis division), Casper Pharma, Teva Pharmaceutical Industries Ltd., Actavis Labs, Inc., UCB S.A., Alkem Labs, Crecent Therapeutics Limited, Baxter, Intas Pharmaceuticals Ltd., and Brown & Burk.
Request to View Discount –
https://www.transparencymarketresearch.com/sample/sample.php?flag=D&rep_id=41975
Dyslexia Drugs Market: Outlook, Competitive Landscape and Forecasts to 2025